[c09aa8]: / clusters / final9knumclusters / clust_2056.txt

Download this file

143 lines (142 with data), 14.5 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
History of unstable or deteriorating cardiac disease within the previous 6 months prior to screening including but not limited to the following:
Uncontrolled cardiac disease
Patient with recent cardiac history (within 6 months) of:
Symptomatic cardiac disease
Have a serious cardiac condition.
Cardiac disease (history of and/or active disease) that would preclude the use of the drugs included in the treatment regimens. This includes but is not confined to:
Participant has active cardiac disease or a history of cardiac dysfunction including any of the following:
History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months of enrollment, or have cardiac atrial or cardiac ventricular lymphoma involvement
history of or current cardiac issues
EXCLUSION - TREATMENT: Cardiac criteria: prolonged QT syndrome; atrial fibrillation/flutter; myocardial infarction within the last 12 months; cardiac echocardiography with LVSF ? 30% or LVEF ? 50%; cardiac dysfunction NYHA III or IV; cardiac echocardiography with clinically significant pericardial effusion
History of arrhythmia requiring an implantable cardiac defibrillator
Subject is undergoing one of the following open elective cardiac, general, or urological surgical procedures: Cardiac procedure (Epicardium); Cardiac procedure (aortic anastomosis or aortotomy suture line); Liver resection; Total splenectomy; On-clamp partial nephrectomy; or Radical nephrectomy.
Subject is undergoing one of the following elective procedures: Cardiac procedure (Epicardium); Cardiac procedure (Aortic Anastomosis or Aortotomy suture line); Liver resection; Total splenectomy; On-clamp partial nephrectomy; or Radical nephrectomy.
Any cardiac finding that is deemed ineligible at the discretion of the investigator
No presence of cardiac disease that, in the opinion of the investigator, increases the risk of ventricular arrhythmia
Cardiac failure, class I-IV
Cardiac arrhythmia not controlled with medical management, evidence of pericardial effusion on imaging that is compromising function
Patients with active renal, cardiac (congestive cardiac failure, myocardial infarction, myocarditis), or pulmonary disease
Have a serious cardiac condition.
Resting QTcF ?470 msec at pretreatment (baseline) or other cardiac or cardiac repolarization abnormality
History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months of enrollment, or have cardiac atrial or cardiac ventricular lymphoma involvement
Patients with known cardiac shunts
Current use of any electronic stimulation device, such as cardiac demand pacemakers, automatic implantable cardiac defibrillator, nerve stimulators, or deep brain stimulators
Any history of clinically significant cardiac arrhythmia, coronary revascularization, ischemic symptoms, or previously documented left ventricular ejection fraction (LVEF) of less than or equal to 45%; a cardiac stress test is required for all patients greater than 50 years old; a cardiac stress test may also be performed for any clinical concern; patients with cardiac ischemia are not eligible
Congestive cardiac failure of >Grade II severity according to the NYHA;
Current use of any electronic stimulation device, such as cardiac demand pacemakers, automatic implantable cardiac defibrillator, nerve stimulators, or deep brain stimulators
History of arrhythmia requiring an implantable cardiac defibrillator.
History or presence of heart failure or left ventricular dysfunction with ejection fraction < 40% within the previous 6 months; if >6 months cardiac function within normal limits and free of cardiac-related symptoms
Have experienced symptomatic cardiac disease that is unresponsive to surgical or medical management
Serious cardiac condition within the last 6 months
Donor must not have any medical condition which would make apheresis more than a minimal risk, and should have the following: \r\n* Family members will be considered for donation if they do not have a history of known cardiac problem and do not have abnormal cardiac findings by physical examination; those with a history of cardiac problems or abnormal cardiac findings by physical examination should undergo a stress evaluation or be evaluated by a cardiologist and deemed eligible to donate
Current use of any electronic stimulation device, such as cardiac demand pacemakers, automatic implantable cardiac defibrillator, nerve stimulators, or deep brain stimulators
Have cardiac pacemakers
Current use of any electronic stimulation device, such as cardiac demand pacemakers, automatic implantable cardiac defibrillator, nerve stimulators, or deep brain stimulators
Patients requiring anti-arrhythmia cardiac medications are NOT eligible
No symptoms of uncontrolled cardiac disease
History of cardiac disease, in particular, supraventricular tachycardia
Active heart (cardiac) disease as defined in the protocol
Presence of cardiac disease that, in the opinion of the investigator, increases the risk of ventricular arrhythmia
No active co-morbid cardiac condition such as active CHF or CAD
Patients with symptomatic cardiac failure unrelieved by medical therapy or evidence of significant cardiac dysfunction by echocardiogram (shortening fraction < 20%)
Patients with symptomatic cardiac disease, or evidence of significant cardiac disease by echocardiogram (i.e., shortening fraction < 25%)
Cardiac or cardiac repolarization abnormality
Cardiac MRI T2* <10ms;
Patients with unstable cardiac status including:
Normal/negative cardiac stress testing with myocardial perfusion imaging OR cardiac catheterization with non-significant angiogram findings reviewed by a cardiology consultant (dose level 3 and >= 40 years old)
Patients with intra-cardiac defibrillators
Have any condition that increases the risk of abnormal ECG or cardiac arrhythmia
Normal cardiac function; patients who have a history of heart disease, or who are over the age of 50 years must have a normal cardiac stress test within the prior 90 days
Subjects with significant cardiac issues
Patients with symptomatic cardiac failure unrelieved by medical therapy or evidence of significant cardiac dysfunction by echocardiogram (shortening fraction < 27%)
History of arrhythmia requiring an implantable cardiac defibrillator
Patient with symptomatic cardiac failure unrelieved by medical therapy or evidence of significant cardiac dysfunction by echocardiogram (shortening fraction < 28%) NOT due to mediastinal mass
Cardiac arrhythmia requiring maintenance medication
Patients must not have serious and inadequately controlled cardiac arrhythmia
Serious cardiac arrhythmia requiring medication
Cardiac arrhythmia not controlled with medical management
Cardiac involvement is defined as the presence of a mean left ventricular wall thickness on echocardiogram greater than 12 mm in the absence of other potential causes of left ventricular hypertrophy (controlled hypertension is allowed) with a noncardiac biopsy showing amyloid, or a positive cardiac biopsy in the presence of clinical or laboratory evidence of involvement. If there is isolated cardiac involvement, then typing of amyloid deposits is recommended.
History or current evidence of cardiac arrhythmia and/or conduction abnormality
Significant active cardiac disease within the previous 6 months from the signing of the ICD, including:
Cardiac:
Cardiac Troponin I within normal limit.
History of arrhythmia requiring an implantable cardiac defibrillator;
Abnormal cardiac status
History or evidence of cardiac disease as indicated by any of the following:
Serious and inadequately controlled cardiac arrhythmia
Patient has active cardiac disease or a history of cardiac dysfunction
Patients with a known history of cardiac disease. This includes:
Known cardiac metastases
A functional cardiac test (e.g., stress treadmill, stress thallium, multigated acquisition scan (MUGA), dobutamine echocardiogram) to rule out cardiac ischemia within 4 months prior to lymphodepletion is required for all patients
Known cardiac metastases
Have abnormal cardiac findings.
Cardiac arrhythmia
Cardiac disease
Active cardiac disease
Significant active cardiovascular or pulmonary disease at study entry ? History of arrhythmia requiring an implantable cardiac defibrillator
Any of the following cardiac diseases currently or within the last 6 months:
DONOR: Donors must not have any medical condition which would make apheresis more than a minimal risk, and should have the following:\r\n* Family members will be considered for donation if they do not have a history of known cardiac problem and do not have abnormal cardiac findings by physical examination; those with a history of cardiac problems or abnormal cardiac findings by physical examination should undergo a stress evaluation or be evaluated by a cardiologist and deemed eligible to donate\r\n* Bilirubin and hepatic transaminases =< 2.5 x upper limit or normal (ULN)\r\n* Adequate hematologic parameters including a hematocrit > 35% for males and 33% for females, white blood cell count of >= 3,000, and platelets >= 80,000\r\n* Foundation for the Accreditation of Cellular Therapy (FACT) laboratories (labs) must be drawn within 7 days of collection and final test results available prior to infusion into the patient; in the case of multiple donations from the donor, the FACT labs must be redrawn within 7 days of each initiation of apheresis (positive serologies are not repeated as they remain positive for lifetime but all other donor labs are performed)
Cardiac troponin I or cardiac troponin T levels above the limit of normal as specified by the manufacturer.
Presence of cardiac metastases
Patient has active cardiac disease or a history of cardiac dysfunction including any of the following:
History of any of the following cardiac conditions:\r\n* Angina requiring treatment with long-acting nitrates\r\n* Angina requiring treatment with short-acting nitrates within 90 days of planned tadalafil administration\r\n* Unstable angina within 90 days of visit 1\r\n* Positive cardiac stress test without documented evidence of subsequent, effective cardiac intervention
T2*MRI cardiac evaluation with T2* >= 20 milliseconds
Significant cardiac conditions or events such as reduced cardiac functions, symptomatic cardiac arrhythmia requiring treatment, congenital long QT syndrome, history of drug-induced QT prolongation, or QTcF correction unmeasurable or more than 450 ms.
Active cardiac disease, defined as (but not limited to):
Cardiac dysrhythmias;
Patients with cardiac atrial or cardiac ventricular lymphoma involvement
Cardiac involvement
Evidence of significant cardiac disease, for example: symptomatic cardiac heart failure (CHF, NYHA class 3), complete bundle branch block, significant atrial or ventricular tachyarrhythmias and any unstable cardiac arrhythmias requiring medication.
Left ventricular ejection fraction < 30%; Note: poor cardiac function predicts for cardiac morbidity, not cardiac mortality; therefore, a cardiology consultant may override the criteria for eligibility
Ongoing cardiac dysrhythmias
History or evidence of cardiac risk.
History of cardiac disease
Active cardiac disease or a history of cardiac dysfunction.
serious cardiac arrhythmia.
Known cardiac disease which precludes their ability to receive planned treatments:\r\n * Angina pectoris that requires the use of anti-anginal medication\r\n * History of documented congestive heart failure\r\n * Serious cardiac arrhythmia requiring medication\r\n * Severe conduction abnormality\r\n * Valvular disease with documented cardiac function compromise; and\r\n * Uncontrolled hypertension defined as blood pressure (BP) that is consistently > 150/90 on antihypertensive therapy at the time of registration; (patients with hypertension that is well controlled on medication are eligible)
Cardiac involvement
Types of cardiac operations permitted:
Patients with history of cardiac dysrhythmia
Patient's with any metallic cardiac implant
Any of the following cardiac criteria: CHF > Class II, cardiac ventricular arrhythmia requiring therapy, unstable angina or new-onset angina, QTcF interval >470ms, abnormal ECHO or MUGA at baseline (LVEF <50%).
History of cardiac disease
Patients with intra-cardiac defibrillators
Abnormal cardiac valve morphology (>= Grade 2) documented by echocardiogram (ECHO)
Subjects with intra-cardiac defibrillators or permanent pacemakers
History or evidence of cardiac risk
Known cardiac/cardiopulmonary disease
History of cardiac disease
Known cardiac/cardiopulmonary disease
Cardiac exclusions:
Patients with intra-cardiac defibrillators
Serious and inadequately controlled cardiac arrhythmia
Active heart (cardiac) disease or a history of cardiac dysfunction as defined in the protocol
Major cardiac disease
Has cardiac status as described in protocol
Patients with intra-cardiac defibrillators or permanent pacemakers.
Cardiac metastases
Abnormal cardiac stress testing within last 6 months
Active cardiac disease;
Current or uncontrolled cardiac disease
Patients with unstable cardiac status including:
Have a serious cardiac condition
Cardiac pacemakers
Patients with any known significant cardiac abnormality.
No known cardiac history (i.e., heart failure, myocardial infarction, or radiation-induced cardiac dysfunction)
Participants with the following underlying medical conditions: multiple myeloma, myasthenia gravis, dysproteinemias, severe cardiac disease, aortic stenosis, primary pulmonary hypertension, cardiac arrhythmia, or severe cardiomyopathy
Unstable cardiac condition
Known cardiac shunt
Patients with known cardiac shunt
Subject has any form of known cardiac arrhythmia
Cardiac disease (cardiac viability assessment)
Patients with cardiac shunts or congenital heart defects
Patient must not have serious and inadequately controlled cardiac arrhythmia
Patients with cardiac shunts
Patients with cardiac shunts
Patients with cardiac shunts
Known or suspected: cardiac shunts
History of cardiac arrhythmia requiring treatment
History of any clinically unstable cardiac condition including class III/IV cardiac failure or right-to left shunts
Cardiac troponin (cTn) levels above the upper limit of normal
Abnormal cardiac status with any of the following:
Known, clinically important cardiac or respiratory disease